Navigation Links
Simmons Hanly Conroy Shareholder Trent Miracle Appointed Co-Lead in Federal Testosterone Replacement Therapy Litigation

CHICAGO, Aug. 5, 2014 /PRNewswire/ -- A federal judge has appointed Simmons Hanly Conroy Shareholder Trent Miracle as co-lead counsel in the national multidistrict litigation pending against the manufacturers of testosterone therapy replacement treatments.

In an order entered July 31, the Honorable Matthew F. Kennelly, of the U.S. District Court for the Northern District of Illinois, appointed Miracle and attorneys Ronald E. Johnson Jr. and Christopher A. Seeger as co-lead counsel for the plaintiffs in the testosterone replacement therapy products liability litigation. Miracle and his co-leads will manage the federal litigation and oversee 29 other attorneys representing men who were seriously injured while taking testosterone replacement therapies.

"This is an important litigation that could impact thousands of men throughout the country," Miracle said. "Judge Kennelly's appointments include some of the nation's top trial attorneys, and I'm looking forward to working with them as we fight for the rights of those unnecessarily harmed while receiving testosterone replacement therapy."

Earlier this year, the U.S. Food & Drug Administration issued a safety announcement about the increased risks associated with low testosterone treatment therapies. Based on new research which found men taking testosterone treatments had a greater chance of suffering a heart attack or stroke, the FDA launched its own investigation of testosterone replacement therapy.

In February 2014, Simmons Hanly Conroy, led by Miracle, filed the first low testosterone lawsuits in the country following the FDA's warning. He was subsequently appointed co-chair of the American Association for Justice's Testosterone Therapy Litigation Group.

The testosterone replacement therapy MDL will help men injured by testosterone treatments receive justice in a timely manner, Miracle said.

"Low testosterone treatments like AndroGel have been heavily marketed to consumers without regard for the possible risks they could cause," Miracle said. "These men looked to testosterone treatments to help them maintain their quality of life and instead were seriously injured."

Simmons Hanly Conroy and its attorneys have held multiple national positions of note in pharmaceutical mass torts litigations. Federal judges have appointed the firm's attorneys to serve on multiple plaintiff steering committees in mass tort litigations including Yaz, DePuy hip implants, Propecia, Transvaginal Mesh Litigation, Lipitor, and more. Their work has resulted in millions of dollars secured on behalf of clients injured by dangerous drugs and defective medical devices.

"My clients can rest assured that they have a national team of skilled trial attorneys working on their behalf to ensure they receive justice," Miracle said.

The case is In Re: Testosterone Replacement Therapy Products Liability Litigation, MDL No. 2545, Case No. 14 C 1748.

About Simmons Hanly Conroy Pharmaceutical Division
SIMMONS HANLY CONROY LLC is a leading national law firm in pharmaceutical litigation. The firm has extensive experience litigating complex medical matters and its attorneys have held leadership roles in cases of national scope on behalf of individuals who have been injured by dangerous drugs or defective medical devices. The firm has recovered more than half a billion dollars in verdicts and settlements in cases involving Bextra, Oxycontin, Vioxx, Yaz and more. Learn more at

Contact: Mark Motley, Chief Marketing Officer
618.259.2222 |

SOURCE Simmons Hanly Conroy
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Positron Appoints Charles Conroy As Chief Operating Officer
2. TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card
3. Sinovac Schedules 2014 Annual Meeting of Shareholders
4. ImmunoCellular Therapeutics Issues Shareholder Letter Providing Update on ICT-107 Program in Newly Diagnosed Glioblastoma
5. Medbox Updates Shareholders on Dividend Issuance
6. Mindray Announced Shareholder Resolutions Post 2013 Annual General Meeting
7. Simcere Pharmaceutical Group Announces Shareholders Approval of the Merger Agreement
8. Pro-Dex, Inc. Announces Plans For Rights Offering To Shareholders
9. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Solta Medical, Inc. - SLTM
10. NW Bio Responds To Shareholder Inquiries Following Immune Therapy Sectors Recent Market Decline
11. Concord Medical Announces the Closing of Acquisition of Its Shares by CEO and COO from Other Shareholders
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology:
(Date:11/26/2015)... TX (PRWEB) , ... November 26, 2015 , ... PRMA ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! ... “We wake up every day excited to rebuild lives and it’s an honor to ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film ... trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 ... with any font, giving users limitless opportunities to stylize and create designs quickly ...
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center software Q-Suite, ... The new Q-Suite 6 platform is based on the latest Java Enterprise standards. By ... piece of software for many key components of the suite. Much of the suite ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... 2015 , ... Finnleo, a leader in the traditional and far-infrared sauna industry, ... far-infrared saunas. , For traditional saunas, Finnleo is offering 20% off ... and Finnleo uses only European Grade A Nordic White Spruce from sustainably grown trees. ...
Breaking Medicine News(10 mins):